

**ROBO Global®**  
**Healthcare Technology and Innovation ETF**  
**Schedule of Investments**  
January 31, 2021 (Unaudited)

Description	Shares	Fair Value	Description	Shares	Fair Value
<b>COMMON STOCK – 99.6%</b>			<b>Spain – 0.9%</b>		
<b>Australia – 0.9%</b>			<b>Health Care – 0.9%</b>		
Health Care – 0.9%			Grifols . . . . .	57,206	\$ 1,688,846
CSL . . . . .	8,049	\$ 1,678,028	<b>Total Spain . . . . .</b>		<b>1,688,846</b>
<b>Total Australia . . . . .</b>		<b>1,678,028</b>	<b>Switzerland – 3.4%</b>		
<b>Belgium – 1.2%</b>			<b>Health Care – 3.4%</b>		
Information Technology – 1.2%			Lonza Group . . . . .	3,325	2,130,452
Materialise ADR * . . . . .	31,958	2,086,538	Roche Holding . . . . .	5,469	1,888,268
<b>Total Belgium . . . . .</b>		<b>2,086,538</b>	Tecan Group . . . . .	4,319	2,097,356
<b>China – 1.3%</b>			<b>Total Switzerland . . . . .</b>		<b>6,116,076</b>
Health Care – 1.3%			<b>United Kingdom – 1.7%</b>		
Ping An Healthcare and Technology * (A) . . . . .	195,200	2,425,572	Health Care – 1.7%		
<b>Total China . . . . .</b>		<b>2,425,572</b>	EMIS Group . . . . .	91,224	1,445,594
<b>Denmark – 0.7%</b>			Smith & Nephew . . . . .	79,549	1,683,874
Health Care – 0.7%			<b>Total United Kingdom . . . . .</b>		<b>3,129,468</b>
GN Store Nord . . . . .	17,601	1,351,269	<b>United States – 82.5%</b>		
<b>Total Denmark . . . . .</b>		<b>1,351,269</b>	Health Care – 76.6%		
<b>France – 2.5%</b>			1Life Healthcare * . . . . .	58,456	2,957,874
Health Care – 2.5%			Abbott Laboratories . . . . .	14,108	1,743,608
Collectis ADR * . . . . .	79,784	2,181,295	ABIOMED * . . . . .	8,571	2,984,852
Eurofins Scientific . . . . .	23,784	2,287,929	Agilent Technologies . . . . .	16,273	1,955,526
<b>Total France . . . . .</b>		<b>4,469,224</b>	Align Technology * . . . . .	3,614	1,898,723
<b>Germany – 1.4%</b>			Alnylam Pharmaceuticals * . . . . .	9,024	1,357,932
Health Care – 1.4%			Axogen * . . . . .	141,629	2,457,263
Siemens Healthineers . . . . .	46,685	2,624,900	Baxter International . . . . .	19,115	1,468,605
<b>Total Germany . . . . .</b>		<b>2,624,900</b>	Becton Dickinson . . . . .	5,295	1,386,178
<b>Italy – 1.3%</b>			BioMarin Pharmaceutical * . . . . .	20,050	1,659,739
Health Care – 1.3%			Bio-Rad Laboratories, CI A * . . . . .	3,590	2,059,834
DiaSorin . . . . .	10,999	2,413,310	BioTelemetry * . . . . .	33,502	2,394,053
<b>Total Italy . . . . .</b>		<b>2,413,310</b>	Boston Scientific * . . . . .	68,251	2,418,815
<b>Japan – 0.6%</b>			Bristol-Myers Squibb . . . . .	23,158	1,422,596
Health Care – 0.6%			Cardiovascular Systems * . . . . .	61,524	2,767,965
Terumo . . . . .	29,600	1,149,281	CareDx * . . . . .	33,974	2,596,633
<b>Total Japan . . . . .</b>		<b>1,149,281</b>	Catalent * . . . . .	21,417	2,464,026
<b>Netherlands – 1.2%</b>			Cerus * . . . . .	191,119	1,259,474
Health Care – 1.2%			Charles River Laboratories International * . . . . .	9,882	2,559,932
Koninklijke Philips . . . . .	38,109	2,081,362	Codexis * . . . . .	101,657	2,367,592
<b>Total Netherlands . . . . .</b>		<b>2,081,362</b>	CONMED . . . . .	14,218	1,590,994
			CryoLife * . . . . .	91,476	2,189,021
			Danaher . . . . .	10,192	2,424,065
			DexCom * . . . . .	6,710	2,515,244
			Editas Medicine, CI A * . . . . .	68,094	4,177,566
			Edwards Lifesciences * . . . . .	22,846	1,886,623
			Exact Sciences * . . . . .	16,235	2,226,793
			Fulgent Genetics * . . . . .	49,612	5,481,629
			Glaukos * . . . . .	33,438	2,965,617
			Globus Medical, CI A * . . . . .	20,261	1,249,901
			Health Catalyst * . . . . .	59,812	2,971,460
			Hologic * . . . . .	24,381	1,943,897
			Illumina * . . . . .	6,675	2,846,487
			Incyte * . . . . .	25,955	2,329,461
			Insulet * . . . . .	9,029	2,412,368
			Integra LifeSciences Holdings * . . . . .	41,632	2,749,377

**ROBO Global®**  
**Healthcare Technology and Innovation ETF**  
**Schedule of Investments**  
**January 31, 2021 (Unaudited)**

Description	Shares	Fair Value	(B) Rate shown is the 7-day effective yield as of January 31, 2021.
Intuitive Surgical * . . . . .	2,984	\$ 2,230,958	
IQVIA Holdings * . . . . .	12,512	2,224,634	
iRhythm Technologies * . . . . .	12,975	2,185,250	ADR - American Depository Receipt
Masimo * . . . . .	6,496	1,662,456	CI - Class
Medpace Holdings * . . . . .	13,639	1,811,123	
Moderna * . . . . .	7,700	1,333,332	As of January 31, 2021, all of the Fund's investments were considered
NanoString Technologies * . . . . .	30,343	2,124,920	Level 1 of the fair value hierarchy, in accordance with the
Natera * . . . . .	26,836	2,861,790	authoritative guidance under U.S. GAAP.
NeoGenomics * . . . . .	44,999	2,385,847	
Nevro * . . . . .	12,242	1,980,633	For the period ended January 31, 2021, there were no transfers in
Novocure * . . . . .	7,929	1,276,252	or out of Level 3.
Omnicell * . . . . .	19,337	2,277,899	
Penumbra * . . . . .	10,707	2,795,491	For information regarding the Trust's policy regarding valuation
PerkinElmer . . . . .	13,632	2,004,858	of investments and other significant accounting policies, please
Quidel * . . . . .	10,095	2,533,542	refer to the Trust's most recent semi-annual and annual financial
Regeneron Pharmaceuticals * . . . . .	4,365	2,199,262	statements.
STAAR Surgical * . . . . .	28,043	2,876,651	
Stryker . . . . .	7,399	1,635,253	ROB-QH-001-1500
Tabula Rasa HealthCare * . . . . .	61,480	3,491,450	
Tactile Systems Technology * . . . . .	42,140	2,298,737	
Teladoc Health * . . . . .	5,745	1,515,703	
Thermo Fisher Scientific . . . . .	4,943	2,519,447	
Veeva Systems, CI A * . . . . .	4,319	1,193,944	
Veracyte * . . . . .	20,366	1,154,752	
Vertex Pharmaceuticals * . . . . .	7,711	1,766,436	
Vocera Communications * . . . . .	65,793	2,891,602	
		<u>139,373,945</u>	
<b>Information Technology – 5.8%</b>			
3D Systems * . . . . .	138,070	4,907,008	
Brooks Automation . . . . .	22,335	1,692,100	
Novanta * . . . . .	11,258	1,406,349	
Nuance Communications * . . . . .	55,817	2,541,906	
		<u>10,547,363</u>	
<b>Total United States . . . . .</b>		<u>149,921,308</u>	
Total Common Stock			
(Cost \$154,118,792) . . . . .		<u>181,135,182</u>	
<b>SHORT-TERM INVESTMENT – 0.4%</b>			
Invesco Government & Agency, CI Institutional, 0.03% (B) . . . . .	639,931	<u>639,931</u>	
Total Short-Term Investment			
(Cost \$639,931) . . . . .		<u>639,931</u>	
Total Investments - 100.0%			
(Cost \$154,758,723) . . . . .		<u>\$ 181,775,113</u>	

Percentages based on Net Assets of \$181,803,455.

\* Non-income producing security.  
(A) Securities sold within terms of a private placement memorandum, exempt from registration under Section 144A of the Securities Act of 1933, as amended, and may be sold only to dealers in that program or other "accredited investors." These securities have been determined to be liquid under guidelines established by the board of Trustees. As of January 31, 2021, the value of these securities amounted to \$2,425,572, representing 1.3% of the Net Assets of the Fund.